CD30 expression is frequently decreased in relapsed classic Hodgkin lymphoma after anti-CD30 CAR T-cell therapy
An Expression of Concern has been raised for this article:
-
Expression of Concern: CD30 expression is frequently decreased in relapsed classic Hodgkin lymphoma after anti-CD30 CAR T-cell therapy
- Volume 84Issue 3Histopathology
- pages: 574-574
- First Published online: December 28, 2023
Mario L. Marques-Piubelli
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorDo Hwan Kim
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorL. Jeffrey Medeiros
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorWei Lu
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorKhaja Khan
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorLorena Isabel Gomez-Bolanos
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorSaxon Rodriguez
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorEdwin R. Parra
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorChi Young Ok
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorAkanksha Aradhya
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorLuisa M Solis
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorYago L. Nieto
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorRaphael Steiner
Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorSairah Ahmed
Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorCorresponding Author
Francisco Vega
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Address for correspondence: F Vega, MD, PhD, Department of Hematopathology, unit 1053, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA, e-mail: [email protected]Search for more papers by this authorMario L. Marques-Piubelli
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorDo Hwan Kim
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorL. Jeffrey Medeiros
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorWei Lu
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorKhaja Khan
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorLorena Isabel Gomez-Bolanos
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorSaxon Rodriguez
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorEdwin R. Parra
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorChi Young Ok
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorAkanksha Aradhya
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorLuisa M Solis
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorYago L. Nieto
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorRaphael Steiner
Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorSairah Ahmed
Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorCorresponding Author
Francisco Vega
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Address for correspondence: F Vega, MD, PhD, Department of Hematopathology, unit 1053, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA, e-mail: [email protected]Search for more papers by this authorMario L. Marques-Piubelli and Do Hwan Kim contributed equally to this study
Abstract
Chimeric antigen receptor (CAR) T-cells anti-CD30 is an innovative therapeutic option that has been used to treat cases of refractory/relapsed (R/R) classic Hodgkin lymphoma (CHL). Limited data are available regarding the CD30 expression status of patients who relapsed after this therapy. This is the first study to show decreased CD30 expression in R/R CHL in patients (n = 5) who underwent CAR T-cell therapy in our institution between 2018 and 2022. Although conventional immunohistochemical assays showed decreased CD30 expression in neoplastic cells in all cases (8/8) the tyramide amplification assay and RNAScope in situ hybridisation detected CD30 expression at different levels in 100% (n = 8/8) and 75% (n = 3/4), respectively. Hence, our findings document that certain levels of CD30 expression are retained by the neoplastic cells. This is not only of biological interest but also diagnostically important, as detection of CD30 is an essential factor in establishing a diagnosis of CHL.
Conflict of interest
FV receives research funding from Geron Corporation and Allogene and received in the last 3 years honoraria from CRISP Therapeutics. The remaining authors have no conflicts of interest.
Open Research
Data availability statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Supporting Information
| Filename | Description |
|---|---|
| his14910-sup-0001-Supinfo.docxWord 2007 document , 24.8 KB |
Table S1. Summary of the treatment strategies for the 5 CHL patients after and before CAR T-cell therapy. Table S2. CD30 quantification in HRS cells using immunohistochemistry (IHC) and immunofluorescence (IF) TSA based. |
| his14910-sup-0002-FigureS1.tifimage/tif, 3.8 MB |
Figure S1. A representative case of CHL with relapsed/persistent disease after brentuximab vedotin (BV) therapy. (A) H&E (40x) section shows HRS cells in a background of lymphocytes and histiocytes. The HRS cells are strongly and uniformly positive for CD30 (B, 20x). |
| his14910-sup-0003-FigureS2.tifimage/tif, 19.8 MB |
Figure S2. RNA Scope to detect mRNA signals for CD30. Representative haematoxylin & eosin (H&E) (A and C, 40×) of treatment naïve classic Hodgkin lymphoma (CHL) cases show CD30 signals composed by >10 dots/cell or >10% dots are in clusters (B and D, 40×), while cases of relapsed/refractory CHL after CAR T-cell therapy (E, G, I, and K 40×) show decreased CD30 signals composed by 1–10 dots/cell or very few dot clusters (F, H, and J, 40×) or negative (L, 40×). |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1Straus DJ, Długosz-Danecka M, Connors JM et al. Brentuximab vedotin with chemotherapy for stage iii or iv classical hodgkin lymphoma (echelon-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematol. 2021; 8; e410–e421.
- 2Ramos CA, Grover NS, Beaven AW et al. Anti-cd30 car-t cell therapy in relapsed and refractory hodgkin lymphoma. J. Clin. Oncol. 2020; 38; 3794–3804.
- 3Younes A, Bartlett NL, Leonard JP et al. Brentuximab vedotin (sgn-35) for relapsed cd30-positive lymphomas. N. Engl. J. Med. 2010; 363; 1812–1821.
- 4Ansell SM, Lesokhin AM, Borrello I et al. Pd-1 blockade with nivolumab in relapsed or refractory hodgkin's lymphoma. N. Engl. J. Med. 2015; 372; 311–319.
- 5van der Weyden CA, Pileri SA, Feldman AL, Whisstock J, Prince HM. Understanding cd30 biology and therapeutic targeting: a historical perspective providing insight into future directions. Blood Cancer J. 2017; 7; e603.
- 6Schwarting R, Gerdes J, Dürkop H, Falini B, Pileri S, Stein H. Ber-h2: a new anti-ki-1 (cd30) monoclonal antibody directed at a formol-resistant epitope. Blood 1989; 74; 1678–1689.
- 7Piris MA, Medeiros LJ, Chang KC. Hodgkin lymphoma: a review of pathological features and recent advances in pathogenesis. Pathology 2020; 52; 154–165.
- 8Alaggio R, Amador C, Anagnostopoulos I et al. The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 2022; 36; 1720–1748.
- 9Campo E, Jaffe ES, Cook JR et al. The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee. Blood 2022; 140; 1229–1253.
- 10Kim JE, Singh RR, Cho-Vega JH et al. Sonic hedgehog signaling proteins and atp-binding cassette g2 are aberrantly expressed in diffuse large b-cell lymphoma. Mod. Pathol. 2009; 22; 1312–1320.
- 11Kim DH, Vega F. Relapsed classic hodgkin lymphoma with decreased cd30 expression after brentuximab and anti-cd30 car-t therapies. Blood 2022; 139; 951.
- 12Wang F, Flanagan J, Su N et al. Rnascope: a novel in situ rna analysis platform for formalin-fixed, paraffin-embedded tissues. J. Mol. Diagn. 2012; 14; 22–29.
- 13Francisco-Cruz A, Parra ER, Tetzlaff MT, Wistuba II. Multiplex immunofluorescence assays. Methods Mole. Biol. 2020; 2055; 467–495.
- 14Al-Rohil RN, Torres-Cabala CA, Patel A et al. Loss of cd30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding. J. Cutan. Pathol. 2016; 43; 1161–1166.
- 15Chen R, Hou J, Newman E et al. Cd30 downregulation, mmae resistance, and mdr1 upregulation are all associated with resistance to brentuximab vedotin. Mol. Cancer Ther. 2015; 14; 1376–1384.
- 16Nathwani N, Krishnan AY, Huang Q et al. Persistence of cd30 expression in hodgkin lymphoma following brentuximab vedotin (sgn-35) treatment failure. Leuk. Lymphoma 2012; 53; 2051–2053.
- 17Faget L, Hnasko TS. Tyramide signal amplification for immunofluorescent enhancement. Methods Mol. Biol. 2015; 1318; 161–172.
- 18Cortés-López M, Schulz L, Enculescu M et al. High-throughput mutagenesis identifies mutations and rna-binding proteins controlling cd19 splicing and cart-19 therapy resistance. Nat. Commun. 2022; 13; 5570.
- 19Czuczman MS, Olejniczak S, Gowda A et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global cd20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin. Cancer Res. 2008; 14; 1561–1570.
Citing Literature
